메뉴 건너뛰기




Volumn 73, Issue 5 SUPPL., 2009, Pages

Risk of Developing Prostate Cancer in the Future: Overview of Prognostic Biomarkers

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

EID: 64349085837     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.02.022     Document Type: Article
Times cited : (25)

References (48)
  • 2
    • 40949147326 scopus 로고    scopus 로고
    • Quality of life and satisfaction with outcome among prostate-cancer survivors
    • Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
    • (2008) N Engl J Med , vol.358 , pp. 1250-1261
    • Sanda, M.G.1    Dunn, R.L.2    Michalski, J.3
  • 3
    • 33846701592 scopus 로고    scopus 로고
    • Cumulative cost pattern comparison of prostate cancer treatments
    • Wilson L.S., Tesoro R., Elkin E.P., et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109 (2007) 518-527
    • (2007) Cancer , vol.109 , pp. 518-527
    • Wilson, L.S.1    Tesoro, R.2    Elkin, E.P.3
  • 4
    • 0034649284 scopus 로고    scopus 로고
    • Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
    • Grover S.A., Dorais M., Paradis G., et al. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. Can Med Assoc J 163 (2000) 1263-1269
    • (2000) Can Med Assoc J , vol.163 , pp. 1263-1269
    • Grover, S.A.1    Dorais, M.2    Paradis, G.3
  • 5
    • 0037126526 scopus 로고    scopus 로고
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 6
    • 39549117783 scopus 로고    scopus 로고
    • Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT Study
    • Rosario D.J., Lane J.A., Metcalfe C., et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT Study. Eur Urol 53 (2008) 777-784
    • (2008) Eur Urol , vol.53 , pp. 777-784
    • Rosario, D.J.1    Lane, J.A.2    Metcalfe, C.3
  • 7
    • 35648951103 scopus 로고    scopus 로고
    • Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL
    • Canby-Hagino E., Hernandez J., Brand T.C., et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology 70 (2007) 748-752
    • (2007) Urology , vol.70 , pp. 748-752
    • Canby-Hagino, E.1    Hernandez, J.2    Brand, T.C.3
  • 8
    • 0026522840 scopus 로고
    • Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
    • Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
    • (1992) JAMA , vol.267 , pp. 2215-2220
    • Carter, H.B.1    Pearson, J.D.2    Metter, E.J.3
  • 9
    • 33646459214 scopus 로고    scopus 로고
    • Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
    • Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
    • (2006) J Natl Cancer Inst , vol.98 , pp. 529-534
    • Thompson, I.M.1    Ankerst, D.P.2    Chi, C.3
  • 10
    • 0028801975 scopus 로고
    • A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
    • Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289-294
    • (1995) JAMA , vol.273 , pp. 289-294
    • Gann, P.H.1    Hennekens, C.H.2    Stampfer, M.J.3
  • 11
    • 0034875454 scopus 로고    scopus 로고
    • Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging
    • Fang J., Metter E.J., Landis P., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58 (2001) 411-416
    • (2001) Urology , vol.58 , pp. 411-416
    • Fang, J.1    Metter, E.J.2    Landis, P.3
  • 12
    • 57149118824 scopus 로고    scopus 로고
    • Defining increased future risk for prostate cancer: evidence from a population based screening cohort
    • Schröder F.H., Roobol M.J., Andriole G.L., et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 181 (2009) 69-74
    • (2009) J Urol , vol.181 , pp. 69-74
    • Schröder, F.H.1    Roobol, M.J.2    Andriole, G.L.3
  • 13
    • 56649091399 scopus 로고    scopus 로고
    • Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
    • Grubb III R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102 (2008) 1524-1530
    • (2008) BJU Int , vol.102 , pp. 1524-1530
    • Grubb III, R.L.1    Pinsky, P.F.2    Greenlee, R.T.3
  • 14
    • 33846959137 scopus 로고    scopus 로고
    • Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years
    • Lilja H., Ulmert D., Björk T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol 25 (2007) 431-436
    • (2007) J Clin Oncol , vol.25 , pp. 431-436
    • Lilja, H.1    Ulmert, D.2    Björk, T.3
  • 15
    • 9644281516 scopus 로고    scopus 로고
    • Prostate cancer screening
    • Catalona W.J. Prostate cancer screening. BJU Int 94 (2004) 964-966
    • (2004) BJU Int , vol.94 , pp. 964-966
    • Catalona, W.J.1
  • 17
    • 35348823195 scopus 로고    scopus 로고
    • The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy
    • Vickers A.J., Ulmert D., Serio A.M., et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 121 (2007) 2212-2217
    • (2007) Int J Cancer , vol.121 , pp. 2212-2217
    • Vickers, A.J.1    Ulmert, D.2    Serio, A.M.3
  • 18
    • 41149091657 scopus 로고    scopus 로고
    • Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study
    • Ulmert D., Cronin A.M., Bjork T., et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6 (2008) 6-13
    • (2008) BMC Med , vol.6 , pp. 6-13
    • Ulmert, D.1    Cronin, A.M.2    Bjork, T.3
  • 19
    • 2442715038 scopus 로고    scopus 로고
    • Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter
    • Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
    • (2004) N Engl J Med , vol.350 , pp. 2239-2246
    • Thompson, I.M.1    Pauler, D.K.2    Goodman, P.J.3
  • 20
    • 33645648583 scopus 로고    scopus 로고
    • Viewpoint: expanding prostate cancer screening
    • Catalona W.J., Loeb S., and Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 144 (2006) 441-443
    • (2006) Ann Intern Med , vol.144 , pp. 441-443
    • Catalona, W.J.1    Loeb, S.2    Han, M.3
  • 22
    • 0027211001 scopus 로고
    • The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
    • Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
    • (1993) J Urol , vol.150 , pp. 110-114
    • Partin, A.W.1    Yoo, J.2    Carter, H.B.3
  • 23
    • 8444251062 scopus 로고    scopus 로고
    • Prostate-specific antigen (PSA) best practice policy
    • American Urological Association (AUA)
    • American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 4 (2000) 267-280
    • (2000) Oncology (Williston Park) , vol.4 , pp. 267-280
  • 24
    • 0029830551 scopus 로고    scopus 로고
    • Age-specific reference ranges for prostate-specific antigen in black men
    • Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
    • (1996) N Engl J Med , vol.335 , pp. 304-310
    • Morgan, T.O.1    Jacobsen, S.J.2    McCarthy, W.F.3
  • 25
    • 33846525375 scopus 로고    scopus 로고
    • Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL
    • Al-Azab R., Toi A., Lockwood G., et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 69 (2007) 103-107
    • (2007) Urology , vol.69 , pp. 103-107
    • Al-Azab, R.1    Toi, A.2    Lockwood, G.3
  • 26
    • 36349014841 scopus 로고    scopus 로고
    • Prostate volume and adverse prostate cancer features: fact not artifact
    • Briganti A., Chun F.K., Suardi N., et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 43 (2007) 2669-2677
    • (2007) Eur J Cancer , vol.43 , pp. 2669-2677
    • Briganti, A.1    Chun, F.K.2    Suardi, N.3
  • 27
    • 35648943184 scopus 로고    scopus 로고
    • High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates
    • Sajadi K.P., Kim T., Terris M.K., et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 70 (2007) 691-695
    • (2007) Urology , vol.70 , pp. 691-695
    • Sajadi, K.P.1    Kim, T.2    Terris, M.K.3
  • 28
    • 55649123911 scopus 로고    scopus 로고
    • PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging
    • Loeb S., Kettermann A., Ferrucci L., et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 54 (2008) 1073-1080
    • (2008) Eur Urol , vol.54 , pp. 1073-1080
    • Loeb, S.1    Kettermann, A.2    Ferrucci, L.3
  • 29
    • 51649101380 scopus 로고    scopus 로고
    • Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era
    • Chen Y.C., Page J.H., Chen R., et al. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 68 (2008) 1582-1591
    • (2008) Prostate , vol.68 , pp. 1582-1591
    • Chen, Y.C.1    Page, J.H.2    Chen, R.3
  • 30
    • 0034644185 scopus 로고    scopus 로고
    • Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
    • Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 (2000) 78-85
    • (2000) N Engl J Med , vol.343 , pp. 78-85
    • Lichtenstein, P.1    Holm, N.V.2    Verkasalo, P.K.3
  • 31
    • 40049098166 scopus 로고    scopus 로고
    • Cumulative association of five genetic variants with prostate cancer
    • Zheng S.L., Sun J., Wiklund F., et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358 (2008) 910-919
    • (2008) N Engl J Med , vol.358 , pp. 910-919
    • Zheng, S.L.1    Sun, J.2    Wiklund, F.3
  • 32
    • 50249119780 scopus 로고    scopus 로고
    • Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations
    • Sun J., Chang B.L., Isaacs S.D., et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 68 (2008) 1257-1262
    • (2008) Prostate , vol.68 , pp. 1257-1262
    • Sun, J.1    Chang, B.L.2    Isaacs, S.D.3
  • 33
    • 34247482327 scopus 로고    scopus 로고
    • Multiple regions within 8q24 independently affect risk for prostate cancer
    • Haiman C.A., Patterson N., Freedman M.L., et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39 (2007) 638-644
    • (2007) Nat Genet , vol.39 , pp. 638-644
    • Haiman, C.A.1    Patterson, N.2    Freedman, M.L.3
  • 34
    • 0036783557 scopus 로고    scopus 로고
    • Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels
    • Lefkowitz G.K., Taneja S.S., Brown J., et al. Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 168 4 Pt. 1 (2002) 1415-1418
    • (2002) J Urol , vol.168 , Issue.4 PART 1 , pp. 1415-1418
    • Lefkowitz, G.K.1    Taneja, S.S.2    Brown, J.3
  • 35
    • 0029045030 scopus 로고
    • Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate
    • Keetch D.W., Humphrey P., Stahl D., et al. Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 154 2 Pt. 1 (1995) 347-351
    • (1995) J Urol , vol.154 , Issue.2 PART 1 , pp. 347-351
    • Keetch, D.W.1    Humphrey, P.2    Stahl, D.3
  • 37
    • 0028902318 scopus 로고
    • Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer
    • Ivanovic V., Melman A., vis-Joseph B., et al. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1 (1995) 282-284
    • (1995) Nat Med , vol.1 , pp. 282-284
    • Ivanovic, V.1    Melman, A.2    vis-Joseph, B.3
  • 38
    • 0031019319 scopus 로고    scopus 로고
    • Transforming growth factor beta as a clinical biomarker for prostate cancer
    • Perry K.T., Anthony C.T., Case T., et al. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49 (1997) 151-155
    • (1997) Urology , vol.49 , pp. 151-155
    • Perry, K.T.1    Anthony, C.T.2    Case, T.3
  • 39
    • 0001693183 scopus 로고    scopus 로고
    • Serum concentrations of transforming growth factor-β1 in patients with benign and malignant prostatic diseases
    • Wolff J.M., Fandel T.H., Borchers H., et al. Serum concentrations of transforming growth factor-β1 in patients with benign and malignant prostatic diseases. Anticancer Res 19 suppl 4A (1999) 2657-2659
    • (1999) Anticancer Res , vol.19 , Issue.SUPPL. 4A , pp. 2657-2659
    • Wolff, J.M.1    Fandel, T.H.2    Borchers, H.3
  • 40
    • 3042823539 scopus 로고    scopus 로고
    • Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer
    • Michalaki V., Syrigos K., Charles P., et al. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90 (2004) 2312-2316
    • (2004) Br J Cancer , vol.90 , pp. 2312-2316
    • Michalaki, V.1    Syrigos, K.2    Charles, P.3
  • 41
    • 0033911711 scopus 로고    scopus 로고
    • Serum interleukin 6 as a prognostic factor in patients with prostate cancer
    • Nakashima J., Tachibana M., Horiguchi Y., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706
    • (2000) Clin Cancer Res , vol.6 , pp. 2702-2706
    • Nakashima, J.1    Tachibana, M.2    Horiguchi, Y.3
  • 42
    • 41749088455 scopus 로고    scopus 로고
    • PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance
    • Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1809
    • (2008) J Urol , vol.179 , pp. 1804-1809
    • Nakanishi, H.1    Groskopf, J.2    Fritsche, H.A.3
  • 43
    • 55649120679 scopus 로고    scopus 로고
    • Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy
    • Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088
    • (2008) Eur Urol , vol.54 , pp. 1081-1088
    • Haese, A.1    de la Taille, A.2    van Poppel, H.3
  • 44
    • 35148826768 scopus 로고    scopus 로고
    • Prostate cancer risk assessment program: a 10-year update of cancer detection
    • Giri V.N., Beebe-Dimmer J., Buyyounouski M., et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 178 (2007) 1920-1924
    • (2007) J Urol , vol.178 , pp. 1920-1924
    • Giri, V.N.1    Beebe-Dimmer, J.2    Buyyounouski, M.3
  • 45
    • 25144445294 scopus 로고    scopus 로고
    • BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian
    • Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7 (2005) 60
    • (2005) MedGenMed , vol.7 , pp. 60
    • Friedenson, B.1
  • 46
    • 2442440933 scopus 로고    scopus 로고
    • BRCA mutations and risk of prostate cancer in Ashkenazi Jews
    • Kirchhoff T., Kauff N.D., and Mitra N. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10 (2004) 2918-2921
    • (2004) Clin Cancer Res , vol.10 , pp. 2918-2921
    • Kirchhoff, T.1    Kauff, N.D.2    Mitra, N.3
  • 47
    • 34147136783 scopus 로고    scopus 로고
    • EPCA-2: a highly specific serum marker for prostate cancer
    • Leman E.S., Cannon G.W., Trock B.J., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69 (2007) 714-720
    • (2007) Urology , vol.69 , pp. 714-720
    • Leman, E.S.1    Cannon, G.W.2    Trock, B.J.3
  • 48
    • 64349089205 scopus 로고    scopus 로고
    • Analysis of a second EPCA-2 epitope as a serum test for prostate cancer (abstract)
    • Leman E., Magheli A., and Cannon G.W. Analysis of a second EPCA-2 epitope as a serum test for prostate cancer (abstract). J Urol 179 (2008) 704
    • (2008) J Urol , vol.179 , pp. 704
    • Leman, E.1    Magheli, A.2    Cannon, G.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.